MCRB vs. ANAB, MAZE, TRVI, SAGE, MNMD, AUTL, STOK, KROS, TRML, and ALT
Should you be buying Seres Therapeutics stock or one of its competitors? The main competitors of Seres Therapeutics include AnaptysBio (ANAB), Maze Therapeutics (MAZE), Trevi Therapeutics (TRVI), Sage Therapeutics (SAGE), Mind Medicine (MindMed) (MNMD), Autolus Therapeutics (AUTL), Stoke Therapeutics (STOK), Keros Therapeutics (KROS), Tourmaline Bio (TRML), and Altimmune (ALT). These companies are all part of the "pharmaceutical products" industry.
Seres Therapeutics vs.
AnaptysBio (NASDAQ:ANAB) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, community ranking, analyst recommendations and earnings.
Seres Therapeutics has higher revenue and earnings than AnaptysBio. AnaptysBio is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, AnaptysBio had 6 more articles in the media than Seres Therapeutics. MarketBeat recorded 11 mentions for AnaptysBio and 5 mentions for Seres Therapeutics. AnaptysBio's average media sentiment score of 0.74 beat Seres Therapeutics' score of 0.15 indicating that AnaptysBio is being referred to more favorably in the media.
59.3% of Seres Therapeutics shares are owned by institutional investors. 33.7% of AnaptysBio shares are owned by insiders. Comparatively, 5.1% of Seres Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
AnaptysBio presently has a consensus price target of $35.11, indicating a potential upside of 90.41%. Seres Therapeutics has a consensus price target of $4.00, indicating a potential upside of 461.80%. Given Seres Therapeutics' higher possible upside, analysts clearly believe Seres Therapeutics is more favorable than AnaptysBio.
Seres Therapeutics received 157 more outperform votes than AnaptysBio when rated by MarketBeat users. Likewise, 71.47% of users gave Seres Therapeutics an outperform vote while only 66.19% of users gave AnaptysBio an outperform vote.
Seres Therapeutics has a net margin of 0.00% compared to AnaptysBio's net margin of -289.75%. Seres Therapeutics' return on equity of 0.00% beat AnaptysBio's return on equity.
AnaptysBio has a beta of 0.02, indicating that its stock price is 98% less volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 2.19, indicating that its stock price is 119% more volatile than the S&P 500.
Summary
Seres Therapeutics beats AnaptysBio on 10 of the 19 factors compared between the two stocks.
Get Seres Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Seres Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:MCRB) was last updated on 3/26/2025 by MarketBeat.com Staff
